Dori Gonzalez-Acevedo CEO of ProcellaRX interviews Assurea’s Co-Founders, Tanya Sharma and Krisha Patel on the Women Leading Validation Podcast. They discuss their entrepreneurial journeys and share the Assurea story. They also share their perspectives on the current challenges and barriers in the biotech industry around digital compliance and the adoption of novel technologies. Listen to
(By Brian Buntz) Tanya Sharma, co-founder of the consulting firm Assurea LLC, helps clients in the life sciences industry navigate regulatory requirements. Sharma is an advocate for women in STEM and the life sciences. Sharma: I came to the U.S. when I was five years old and became interested in biomanufacturing. I worked in the labs
The article highlights the persistent challenges and disparities faced by women entrepreneurs in the United States, particularly in the biotech and pharmaceutical sectors. Despite women-owned businesses accounting for 40% of US enterprises, women-led startups received only 2.3% of venture capital funding in 2020. This imbalance is further exemplified by the fact that 92% of CEOs
Tanya Sharma was interviewed by Rizwan Chaudhrey of the RSK Life Science Media in London during Terrapinn’s Advanced Therapies Congress in May 2022 where Assurea participated in the Startup Zone. Rizwan met Tanya Sharma again in September 2022 at the Phacilitate Advanced Therapies UK event and recorded an update on ISPE Women in Pharma and
Data integrity translates into the consistency, completeness, and accuracy of data. It is required in all aspects of biopharmaceutical development and manufacturing, including emerging technologies like block chain, as you introduce them into your Quality Management Systems. Consistency, standardization, and traceability are some of the many issues we face when it comes to data integrity. Once
ATMPS Ltd, a UK developer of blockchain-based cell orchestration platforms for advanced therapies is collaborating with US digital compliance consultancy, Assurea, to develop a fully compliant blockchain approach for end-to-end supply chain management of cell and gene therapies. Read the full story here